Defibrotide

What is Defibrotide?

Defibrotide is an oligonucleotide mixture derived from porcine mucosal deoxyribonucleic acid (DNA). It is a medication primarily used for the treatment of severe Hepatic Veno-Occlusive Disease (VOD), also known as Sinusoidal Obstruction Syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT). This life-threatening condition involves the blockage of small blood vessels in the liver, leading to significant liver damage.

Unlike traditional anticoagulants, Defibrotide is not classified as a direct blood thinner. Instead, it acts as an antithrombotic agent with a unique mechanism that helps restore the balance of the vascular endothelium. Its introduction has been a significant advancement in managing VOD, a severe complication that can have devastating outcomes for patients undergoing HSCT.

How Does it Work?

The mechanism of action of Defibrotide is complex and multifaceted, primarily focusing on protecting and restoring the function of the vascular endothelial cells that line blood vessels. In VOD, these cells become damaged, leading to a prothrombotic state, inflammation, and vessel occlusion. Defibrotide exerts its therapeutic effects through several pathways:

• Endothelial Protection: It protects endothelial cells from damage caused by chemotherapy, radiation, and inflammatory mediators, which are common triggers for VOD in HSCT patients.
• Enhanced Fibrinolysis: Defibrotide promotes the activity of enzymes involved in fibrinolysis, the natural process of breaking down blood clots. It does this by increasing the levels of tissue plasminogen activator (t-PA) and decreasing plasminogen activator inhibitor-1 (PAI-1), thereby shifting the balance towards clot dissolution.
• Anti-inflammatory Effects: It reduces the adhesion of leukocytes to the endothelium and modulates the release of inflammatory cytokines, thereby mitigating the inflammatory response that contributes to VOD progression.
• Reduced Platelet Aggregation: Defibrotide has been shown to inhibit platelet activation and aggregation, further contributing to its antithrombotic properties without causing significant systemic anticoagulation.

By addressing these key aspects of endothelial dysfunction, Defibrotide helps to restore blood flow through the liver sinusoids, reduce congestion, and prevent further damage to liver tissue.

Medical Uses

The primary and most critical medical use for Defibrotide is the treatment of severe hepatic veno-occlusive disease (VOD) with renal or pulmonary dysfunction in adults and pediatric patients undergoing hematopoietic stem cell transplantation (HSCT). This condition is characterized by signs and symptoms such as hyperbilirubinemia, hepatomegaly, ascites, and weight gain, often accompanied by kidney or lung complications.

VOD is a life-threatening complication, and early diagnosis and treatment are crucial. Defibrotide is typically initiated once a diagnosis of severe VOD has been made, often in a hospital setting where intensive monitoring is available. It is not indicated for the prevention of VOD but is a critical intervention once the condition has manifested and progressed to a severe state.

Dosage

Defibrotide is administered intravenously (IV). The recommended dosage for adults and pediatric patients is typically 6.25 mg/kg body weight every 6 hours, for a total daily dose of 25 mg/kg. Each dose is infused over a 2-hour period.

The duration of treatment is usually at least 21 days or until VOD resolution. Resolution of VOD is defined as a sustained decrease in total bilirubin and resolution of other VOD symptoms. Treatment may be continued for longer than 21 days if the patient's VOD symptoms have not resolved. The precise dosage and duration of treatment are determined by the treating physician based on the patient's individual response and clinical status. No dosage adjustments are typically required for patients with renal or hepatic impairment.

Side Effects

Like all medications, Defibrotide can cause side effects. The most common and significant side effect is hemorrhage (bleeding). This is due to its antithrombotic properties, even though it is not a direct anticoagulant. Common bleeding-related side effects include:

• Epistaxis (nosebleeds)
• Gastrointestinal bleeding (e.g., melena, hematochezia)
• Hematuria (blood in urine)
• Petechiae or ecchymosis

Other common side effects that are not related to bleeding may include:

• Hypotension (low blood pressure)
• Diarrhea
• Nausea and vomiting
• Headache
• Sepsis
• Pneumonia

Serious side effects, though less common, can include severe or fatal hemorrhage, hypersensitivity reactions (including anaphylaxis), and infusion-related reactions. Patients receiving Defibrotide are closely monitored for signs of bleeding or other adverse reactions. Defibrotide is contraindicated in patients with active bleeding requiring blood transfusion or in patients with known hypersensitivity to the drug.

Drug Interactions

Caution is advised when Defibrotide is administered concurrently with other medications that affect coagulation or platelet function, as this may increase the risk of bleeding. These include:

• Anticoagulants: Medications such as warfarin, heparin, or direct oral anticoagulants (DOACs) may increase the risk of hemorrhage when used with Defibrotide.
• Antiplatelet Agents: Drugs like aspirin, clopidogrel, or other NSAIDs can also enhance the risk of bleeding.

Patients should inform their healthcare provider about all medications, supplements, and herbal products they are currently taking before starting Defibrotide treatment. Close monitoring for signs of bleeding is essential when Defibrotide is co-administered with these agents.

FAQ

What is Hepatic Veno-Occlusive Disease (VOD)?

VOD, or Sinusoidal Obstruction Syndrome (SOS), is a severe and potentially life-threatening complication of hematopoietic stem cell transplantation (HSCT), where the small blood vessels in the liver become blocked, leading to liver damage.

Who is Defibrotide prescribed for?

Defibrotide is prescribed for adults and children diagnosed with severe VOD (SOS) that presents with renal or pulmonary dysfunction, typically after HSCT.

How is Defibrotide administered?

Defibrotide is administered intravenously (IV) as an infusion over a 2-hour period, typically four times a day.

Is Defibrotide a blood thinner?

While Defibrotide has antithrombotic properties and helps dissolve clots, it is not considered a traditional anticoagulant (blood thinner) like heparin or warfarin. Its mechanism is more focused on endothelial protection and enhancing natural fibrinolysis.

How long does Defibrotide treatment last?

Treatment typically lasts for at least 21 days or until the resolution of VOD symptoms, which is characterized by a sustained decrease in total bilirubin levels.

Products containing Defibrotide are available through trusted online pharmacies. You can browse Defibrotide-based medications at ShipperVIP or Medicenter.

Summary

Defibrotide represents a vital therapeutic option for patients suffering from severe Hepatic Veno-Occlusive Disease (VOD) with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. Its unique mechanism of action involves protecting endothelial cells, enhancing fibrinolysis, reducing inflammation, and inhibiting platelet aggregation, thereby helping to restore proper liver microcirculation. While effective, careful monitoring for bleeding and potential drug interactions is essential. As a specialized treatment for a critical condition, Defibrotide plays a crucial role in improving outcomes for this vulnerable patient population.